What question did this study set out to answer?

To establish wild-type minimum inhibitory concentration (MIC) distributions and epidemiological cutoff values (ECVs) for fluconazole, itraconazole, posaconazole, and voriconazole against the Cryptococcus neoformans-Cryptococcus gattii species complex.

September 5, 2012Antimicrobial Agents and ChemotherapyOpen Access

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole

View Full Paper

Ask AI

Bookmark

Authors

AEAna Espinel‐IngroffVirginia Commonwealth University Medical Center AAAna Isabel AllerHospital Universitario de Valme RCRafael CantónManhattan Institute for Policy Research

Discussion

Member takes

Implication

Multicenter surveillance study establishes triazole cutoff values in Cryptococcus neoformans and Cryptococcus gattii, aiding the detection of acquired drug resistance.

Key Points

To establish wild-type minimum inhibitory concentration (MIC) distributions and epidemiological cutoff values (ECVs) for fluconazole, itraconazole, posaconazole, and voriconazole against the Cryptococcus neoformans-Cryptococcus gattii species complex.
Aggregated 2,985 to 5,733 CLSI MICs for C. neoformans and 705 to 975 MICs for C. gattii across 15 to 24 international laboratories spanning 10 countries.
Evaluated standardized CLSI RPMI and yeast nitrogen base (YNB) media to define ECVs capturing ≥95% of the modeled wild-type population across molecular types.
Fluconazole RPMI ECVs were established at 8 μg/ml for VNI, nontyped C. gattii, VGI, VGIIa, and VGIII; 16 μg/ml for nontyped C. neoformans, VNIII, and VGIV; and 32 μg/ml for VGII.
Posaconazole ECVs were 0.25 μg/ml for nontyped C. neoformans and VNI, and 0.5 μg/ml for nontyped C. gattii and VGI; itraconazole ECVs ranged from 0.25 μg/ml (VNI) to 1 μg/ml (VGIV).
Voriconazole ECVs were defined as 0.12 μg/ml for VNIV, 0.25 μg/ml for nontyped C. neoformans, nontyped C. gattii, VNI, VNIII, VGII, and VGIIa, and 0.5 μg/ml for VGI.

Cite This Study

Espinel‐Ingroff et al. (2012) studied this question.

synapsesocial.com/papers/6a702f5835aa2c282ce17b53 https://doi.org/10.1128/aac.01115-12

View Full Paper

Ask AI

Bookmark

Implication

Multicenter surveillance study establishes triazole cutoff values in Cryptococcus neoformans and Cryptococcus gattii, aiding the detection of acquired drug resistance.

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole

Discussion

Member takes

Implication

Key Points

Cite This Study

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider